Kyprolis (Carfilzomib) is an anti-cancer medicine that inhibits the growth and spread of cancer cells in the body. Kyprolis is sometimes used with other drugs such as dexamethasone or lenalidomide and administered by intravenous infusion to treat patients with blood cancer or multiple myeloma that affect plasma cells. Kyprolis is a second-generation proteasome inhibitor that irreversibly binds to the threonine-containing active site at the N-terminus of the 20S proteasome (the proteolytic core particle in the 26S proteasome). The proteasome is a cellular complex that breaks down proteins and is believed to play a key role in the degradation of various proteins involved in cell cycle regulation, apoptosis and angiogenesis. In vitro, Kyprolis has shown anti-proliferative and pro-apoptotic activities in solid and haematological tumour cells.
Access Full Description of this report at:-
https://www.nextmsc.com/report/kyprolis-carfilzomib-market
Competitive Landscape :
The Kyprolis market comprises of various market players such as PharmaCore Biotech, Avra Laboratories Private Limited, Suzhou Bichal Biological Technology Co., Ltd, Hangzhou Longshine Bio-Tech Co., Ltd, Qilu Pharma, and Chongqing Pharmaceutical Research Institute among others. Strategic alliances, acquisitions and innovations along with R&D are key strategies used by market players to maintain market dominance. For instance, in June 2021, Natco Ltd. received approval for the management and sale of carfilzomib in 10 mg and 60 mg doses. The company is a collaboration between Natco Ltd. and Creckenridge Pharmaceuticals to market the product in the United States. Also, in July 2021, BeiGene announced that the National Medical Products Administration (NMPA) has approved KYPROLIS (carfilzomib) for injection in combination with dexamethasone for the treatment of relapsed or refractory (R / R) multiples who have received at least two treatment adult myeloma patients. The above therapies include proteasome inhibitors and immunomodulators. In the framework of strategic cooperation with Amgen, KYPROLIS obtained a license from BeiGene in China.
Market Dynamics and Trends:
The main factor driving the growth of the Kyprolis market is the rise in the number of people suffering from blood cancer. Globally, around 720,000 people die from blood cancer every year. Carfilzomib has several advantages over traditional cancer treatment technologies such as its improved efficacy, decreased adverse reactions compared with proteasome inhibitor therapy, reduced possibility of heart failure and dyspnoea. This in turn is expected to drive the Kyprolis market growth. Currently, the number of approved treatments for myeloma in the world is limited. This provides a good opportunity for suppliers to effectively create new and effective carfilzomib products that can get faster approvals.
However, high administration costs, and lack of awareness among people about the treatment techniques of cancer are factors expected to restrain the growth of the Kyprolis market to some extent. On the other hand, suppliers are conducting research on such drugs to treat solid tumours, which is expected to create ample growth opportunities for the market in the coming years.
Request sample copy of this report at:-
https://www.nextmsc.com/kyprolis-carfilzomib-market/request-sample
Market Segmentations and Scope of the Study:
The Kyprolis market is segmented by type, by application and by geography. Based on type the market is divided into 60mg Injection, 10mg Injection, 30mg Injection. Based on application, the market is segmented into hospitals, clinics and drug centres. Based on geography, the market is divided into North America, Europe, Asia-Pacific, and RoW.
Geographical Analysis:
North America holds the lion share of Kyprolis (Carfilzomib) market during the forecast period. This is due to certain micro and macro-environmental factors leading to more and more blood and bone marrow cancers in the region. In August 2020, Amgen (AMGN) stated that the U.S. Food and Drug Administration has approved the expansion of prescribing information for KYPROLIS or carfilzomib in the U.S. to include its combination with DARZALEX or daratumumab plus dexamethasone or DKd. It is used to treat patients with relapsed or refractory multiple myeloma who have received first to third line treatment. Additionally, a recent clinical trial conducted by the Multiple Myeloma Research Consortium has shown that a single dose of carfilzomib has been shown to be very effective in patients who have received at least 2 prior therapies (including bortezomib and thalidomide) but have not failed. An important conclusion is that even patients with basal neuropathy can successfully tolerate a single dose of carfilzomib without any possibility or deterioration. Furthermore, a recent study conducted by a syndicated company in the United States concluded that carfilzomib combined with thalidomide as induction therapy for newly discovered multiple myeloma patients was shown to be highly feasible and effective.
However, Asia-Pacific is expected to show a steady rise in the Kyprolis market owing to the rising awareness among people about cancer treatments, along with growing disposable income, increasing demand for advanced drugs and high prevalence of cancer disease.
KEY MARKET SEGMENTS:
- Kyprolis (carfilzomib) Market- By Type:
- 60 mg Injection
- 10 mg Injection
- 30 mg Injection
- Kyprolis (carfilzomib) Market- By Application:
- Hospitals
- Clinics
- Drug centres
- Kyprolis (carfilzomib) Market- By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- RoW
- Brazil
- Saudi Arabia
- South Africa
- Rest of world
Contact:
Phone Number: +1-217-650-7991
E-mail: info@nextmsc.com
About Next Move Strategy Consulting:
Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.
For more insights, please visit, https://www.nextmsc.com
